Created at	Source	Raw Value	Validated value
Dec. 22, 2022, noon	usa	In Phase 1/2, Incidence of solicited adverse events;In Phase 1/2, Incidence of unsolicited adverse events;In Phase 3, efficacy after the second dose	In Phase 1/2, Incidence of solicited adverse events;In Phase 1/2, Incidence of unsolicited adverse events;In Phase 3, efficacy after the second dose
Dec. 7, 2022, 4 a.m.	usa	Incidence of solicited adverse events;Incidence of unsolicited adverse events	Incidence of solicited adverse events;Incidence of unsolicited adverse events